Jaguar Health's Crofelemer Shows Benefit for Intestinal Failure (IF) in Third Rare Congenital Enteropathy Disorder

SAN FRANCISCO, CA / ACCESS Newswire / October 21, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (link) (Jaguar) today announced that Jaguar family company Napo Pharmaceuticals (Napo) has been continuing to provide the company's novel crofelemer powder for oral solution for several weeks for the treatment of intestinal failure (IF) in an infant patient with GUCY2C mutation resulting in congenital sodium diarrhea (CSD). Liquid oral crofelemer therapy is well tolerated by this patient and has demonstrated reduced needs for daily and weekly parenteral support (PS) with no significant clinical or laboratory abnormalities. CSD due to mutation of the GUCY2C gene is the third IF-related congenital enteropathy being evaluated under expanded access, in addition to pediatric microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF), for which crofelemer has demonstrated benefit in reducing weekly parenteral support needs normalized to body weight. The company plans to file a New Drug Application (NDA) for crofelemer for MVID in mid-2027 to obtain FDA approval based on data that will include results from an ongoing pivotal trial which has completed enrollment.